Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling by array of MCF-7 and MDA-MB-213 cells treated with docetaxel

ABSTRACT: Two breast cancer cell lines, MCF-7 and MDA-MB-213, were treated progressively with docetaxel.

ORGANISM(S): Homo sapiens

SUBMITTER: Hansen SN

PROVIDER: S-ECPF-MEXP-3982 | biostudies-other | 2015 Jun

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.

Project description: Not available

| S-EPMC4905937 | biostudies-literature

MDA-MB-468 cells treated with docetaxel or EZH2i+AKTi

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-07-08 | GSE251710 | GEO

Phenotypic and microRNA transcriptomic profiling of the MDA-MB-231 spheroid-enriched CSCs with comparison of MCF-7 microRNA profiling dataset.

Project description: Not available

| S-EPMC5511503 | biostudies-literature

Secretome profiling of <i>Artemisia absinthium</i> extract-loaded polymeric nanoparticle-treated MCF-7 and MDA-MB-231 revealed perturbation in microtubule assembly and cell migration.

Project description: Not available

| S-EPMC10502211 | biostudies-literature

MDA-MB-468 cells treated with docetaxel or EZH2i+AKTi I

Project description:Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy, however responses are typically short-lived1,2. Thus, there is an urgent need to develop more effective treatments. PI3K pathway components represent plausible therapeutic targets, as approximately 70% of TNBCs have PIK3CA/AKT1/PTEN alterations3–6. However, unlike hormone receptor-positive tumors, it is still unclear if or how PI3K pathway inhibitors will be effective in triple-negative disease7. Here we identify a promising AKT inhibitor-based therapeutic combination for TNBC. Specifically, we show that AKT inhibitors potently synergize with agents that suppress the histone methyltransferase, EZH2, and promote robust tumor regression in multiple TNBC models in vivo. AKT and EZH2 inhibitors exert these effects by first cooperatively driving basal-like TNBC cells into a more differentiated, luminal-like state, which cannot be effectively induced by either agent alone. Once differentiated, these agents kill TNBCs by hijacking signals that normally drive mammary gland involution. Finally, using machine learning approach, we developed a classifier that can be used for patient selection. Together these findings identify a promising therapeutic strategy for this highly aggressive tumor type and illustrate how deregulated epigenetic enzymes can insulate tumors from oncogenic vulnerabilities. These studies also reveal how developmental tissue-specific cell death pathways may be co-opted for therapeutic benefit.

2024-07-08 | GSE250632 | GEO

MDA-MB-468 cells treated with docetaxel or EZH2i+AKTi II

2024-07-08 | GSE251708 | GEO

Differential Epigenetic Effects of Atmospheric Cold Plasma on MCF-7 and MDA-MB-231 Breast Cancer Cells.

Project description: Not available

| S-EPMC4456358 | biostudies-literature

The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.

Project description: Not available

| S-EPMC9584993 | biostudies-literature

Screening of Specific and Common Pathways in Breast Cancer Cell Lines MCF-7 and MDA-MB-231 Treated with Chlorophyllides Composites.

Project description: Not available

| S-EPMC9229827 | biostudies-literature